Fresenius Medical Care AG & Co. KGaA's stock plummeted 8.50% during Tuesday's intraday session.

The sharp decline follows the company's release of its 2026 financial guidance, which analysts and investors found underwhelming. The German dialysis specialist forecast "broadly flat" revenue growth for the year, falling short of analyst expectations for approximately 4.3% growth. Furthermore, the company expects adjusted operating profit to range from a mid-single-percentage digit rise to a fall of the same proportion.

Analysts noted that this outlook suggests intensifying headwinds are offsetting anticipated cost savings from efficiency programs. The guidance also indicates the company will face regulatory challenges in 2026, after benefiting from favorable Medicare payment policies in the previous year. Concerns were further amplified by a 0.2% decline in U.S. treatment volumes during the fourth quarter, marking a return to negative territory.